ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine
News Mar 05, 2013
The patent includes claims covering composition of matter as well as methods of use. Specifically, the claims encompass immunogens comprising a CD133 epitope and variants thereof as well as methods of using such immunogens in immunization and to elicit cytotoxic T lymphocyte responses that are specific for tumor cells expressing HLA-A2.
“This issued patent provides significant protection for ICT-121 with what we believe are broad claims, and is an important addition to ImmunoCellular’s intellectual property estate for our cancer vaccines and monoclonal antibodies,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We believe that our growing IP asset strengthens our leadership position in the cancer immunotherapy field, and we look forward to continuing to advance our cancer immunotherapy product candidates through the development process.”
ICT-121 is a dendritic cell vaccine. CD133 is highly expressed on cancer stem cells on most solid tumors, including brain, colon, non-small cell lung, melanoma, pancreatic and breast cancers. ImmunoCellular plans to support an investigator-sponsored, 20-patient phase I trial in recurrent glioblastoma at Cedars-Sinai Medical Center.
Multidisciplinary Study Suggests New Strategy for Drug DiscoveryNews
A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, , suggest a new strategy for drug discovery.READ MORE
Cold and Flu Season is Well Under Way But Don't Stifle a Sneeze Warn DoctorsNews
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors. One young man managed to rupture the back of his throat during this manoeuvre, leaving him barely able to speak or swallow, and in considerable pain.READ MORE